Merck completed its acquisition of Acceleron Pharma for about $11.5 billion, the drugmaker said Nov. 22. Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share ...

Fusion startups have been on a fundraising tear lately, and a young startup, Acceleron Fusion, is joining the pack, having raised $15 million of a targeted $23.7 million round, according to an SEC ...

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring ...

(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Keytruda is far and away Merck’s top-selling product, but the cancer immunotherapy’s patents will expire in seven years and the pharmaceutical giant is looking around for drugs that could succeed it.

Positive effects also demonstrated on reducing spleen size and life-threatening iron overload in the spleen, kidney and liver CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc., a ...

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...

Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...

It's been an up-and-down kind of year so far for Acceleron Pharma (XLRN +0.00%). In September, the biotech announced disappointing phase 2 results for ACE-083 in treating facioscapulohumeral muscular ...

Acceleron Pharma (XLRN +0.00%) hasn't generated much excitement for investors so far this year. The stock is down close to 5% year to date while the broader market indexes are up solidly. The biotech ...